UPDATE: EMA green light for weight-loss product under fire from French and Irish regulators
This article was originally published in SRA
Executive Summary
The decision by the European Medicines Agency's committee for evaluating human drugs (CHMP) to recommend the approval of Orexigen's weight loss combination product Mysimba (naltrexone/bupropion) is under fire.